Dr. Atrash on the BELLINI Trial Results in Relapsed/Refractory Multiple Myeloma

Video

In Partnership With:

Shebli Atrash, MD, discusses the results of the BELLINI trial examining patients with relapsed/refractory multiple myeloma.

Shebli Atrash, MD, a physician in hematology and medical oncology at Levine Cancer Institute, Atrium Health, discusses the results of the BELLINI trial examining patients with relapsed/refractory multiple myeloma.

The phase III BELLINI trial compared venetoclax (Venclexta) versus placebo combined with bortezomib (Velcade) and dexamethasone in patients with relapsed/refractory multiple myeloma, explains Atrash. The trial met its primary endpoint of progression-free survival and showed venetoclax is superior to placebo; however, the risk of death increased in the venetoclax arm, says Atrash.

Patients were enrolled in the BELLINI trial regardless of translocation status or BCL-2 status, but results showed that patients with t(11;14) or high BCL-2 expression derived the most benefit from venetoclax. Going forward, Atrash recommends trials using venetoclax to target this patient population with multiple myeloma.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD